Peptide CDMO Market to Expand at 15.0% CAGR by 2031 | Bachem, PolyPeptide, CordenPharma

Los Angeles, United States - QY Research has unveiled its latest study titled "Global Peptide CDMO Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031." This newly released report delivers a comprehensive overview of the global Peptide CDMO market, analyzing the forces shaping its growth trajectory and providing valuable insights for stakeholders, investors, and industry professionals. the research covers key areas including market dynamics, segmentation, regional performance, competitive landscape, and emerging technology trends that are redefining industry standards. Backed by reliable data and expert analysis, the report serves as a trusted guide to understanding both microeconomic and macroeconomic factors driving market evolution.

The global market for Peptide CDMO was estimated to be worth US$ 4235 million in 2024 and is forecast to a readjusted size of US$ 11080 million by 2031 with a CAGR of 15.0% during the forecast period 2025-2031.

Download Free Sample PDF Report (with full TOC, tables, and charts) To Explore Detailed Insights and Forecasts @ https://qyresearch.in/request-sample/pharma-healthcare-peptide-cdmo-global-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Peptides are synthesized by coupling the carboxyl group of one amino acid to the amino group of another amino acid molecule. Due to the possibility of unintended reactions, protecting groups are common necessary. Chemical peptide synthesis most commonly starts at the carboxyl end of the peptide, and thus progress toward the amino-terminus. This is the opposite direction of protein biosynthesis. A contract development and manufacturing company (CDMO) is a company within the pharmaceutical industry that provides drug development and manufacturing services. Pharmaceutical companies partner with CDMOs as a way to outsource drug development and drug manufacturing. CDMO peptides production via contract peptide manufacturing is to optimize process development and achieve highly efficient conversion at every amino acid coupling to produce a high-purity crude synthetic custom peptide and minimize the demands on downstream processing.

The Peptide CDMO (Contract Development and Manufacturing Organization) market is driven by the increasing demand for peptide-based therapeutics. Peptides are gaining significant traction in the pharmaceutical industry due to their high specificity, targeted action, and fewer side effects compared to traditional small-molecule drugs. As a result, there is growing interest in developing and manufacturing peptides for a wide range of indications, including oncology, diabetes, cardiovascular diseases, and neurological disorders. This shift is coupled with the rise in personalized medicine, where peptides are seen as promising candidates for tailored therapies. Peptide CDMOs are playing a crucial role by providing specialized services like synthesis, purification, and formulation, enabling pharmaceutical companies to bring peptide-based drugs to market faster and more efficiently. Additionally, advancements in peptide synthesis technologies and the increasing outsourcing trend by biopharmaceutical companies are fueling growth in this sector.

Despite the positive growth drivers, the Peptide CDMO market faces several challenges. One of the main hurdles is the complexity involved in peptide synthesis and manufacturing, particularly for large-scale production. Peptides are often fragile and prone to degradation, requiring strict control over production processes, which can be both time-consuming and costly. Additionally, the high costs of peptide synthesis, purification, and formulation pose significant barriers to entry for smaller players, limiting competition and innovation in the market. Furthermore, regulatory challenges are a concern, as peptides often face more stringent requirements during the clinical development and commercialization stages compared to traditional small-molecule drugs. These challenges can result in delays in drug development and increased production costs, which could ultimately impact the profitability of peptide CDMOs.

Global key peptide CDMO producers include Bachem, PolyPeptide, CordenPharma, and others. The top five manufacturers together account for 40% of the market share, with the largest manufacturer being Bachem with 17%. At the sales level, North America is the largest sales market with a market share of over 50%, followed by Europe and China with 33% and 9% respectively.

Competitive Landscape: -

Bachem
PolyPeptide
CordenPharma
AmbioPharm
USV Peptides
Thermofischer
Bio Basic
JPT
Genscript
Xinbang Pharma
ScinoPharm
SN Biopharm
CBL
Piramal Pharma
CPC Scientific

The competitive landscape is a must-have information for the market players to withstand the competition present in the global Peptide CDMO market. This further helps the market participants to develop effective strategies to optimize their market positions. Moreover, the competitive analysis helps them to determine potential advantages as well as barriers within the global Peptide CDMO market. This way, they can monitor how their competitors are implementing various strategies including pricing, marketing, and distribution.

Market Drivers and Restraints -

This section of the Peptide CDMO report discusses various drivers and restrains that have shaped the global market. The detailed study of numerous drivers of the market enable readers to get a clear perspective of the market, which includes market environment, government policies, product innovations, breakthroughs, and market risks.

The research report also points out the myriad opportunities, challenges, and market barriers present in the global Peptide CDMO market. The comprehensive nature of the information will help the reader determine and plan strategies to benefit from. Restrains, challenges, and market barriers also help the reader to understand how the company can prevent itself from facing downfall.

Regional Insights -

The report takes readers on a journey through four key regions: United States, Asia-Pacific, and EMEA. Key nations like the United States, Germany, the United Kingdom, China, Japan, South Korea, and more are thoroughly examined. The data is presented in a timeline from 2024 as the base year, with projections extending to 2031.

North America: United States, Canada, Mexico

Latin America: Brazil and other key markets

Asia Pacific: China, Japan, South Korea, India, ASEAN countries

Europe, Middle East & Africa (EMEA): Major European economies, GCC countries, and African nations

The report provides a region-wise breakdown of market share, consumption trends, and future prospects.

Detailed of Peptide CDMO Market Segmentation -

The report offers great insights into important segments of the global Peptide CDMO market while concentrating on their CAGR, market size, market share, and future growth potential. The global Peptide CDMO market is mainly segmented according to type of product, application, and region. Each segment in these categories is extensively researched to become familiar with their growth prospects and key trends. Segmental analysis is highly important to identify key growth pockets of a global market. The report provides specific information on the market growth and demand of different products and applications to help players to focus on profitable areas of the global Peptide CDMO market.

Segmentation By Type :-

APIs and Intermediates
FDF

Segmentation By Application -

Commercial
Academic Research
Other

This segmentation helps identify high-growth opportunities and niche segments for investors and businesses.

Request for Pre-Order Enquiry On This Exclusive Report @ https://qyresearch.in/pre-order-inquiry/pharma-healthcare-peptide-cdmo-global-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Why This Report is a Must-Have -

ᗒ Historical Analysis (2020-2024) & Forecasts (2025-2031): Gain a clear understanding of market trends and future growth potential.

ᗒ Comprehensive Market Segmentation: Detailed breakdown by Type, Application, and Region to identify lucrative opportunities.

ᗒ Competitive Landscape: Insights into key players, their market share, and strategic developments like mergers, acquisitions, and expansion plans.

ᗒ Drivers & Restraints: Understand the factors shaping the market's growth and the challenges that could impact your strategy.

ᗒ Expert Opinions & Market Dynamics: Benefit from expert analysis to navigate market risks and capitalize on emerging trends.

Peptide CDMO Market Report Objectives -

(1) Analyzing the size of the global Peptide CDMO market on the basis of value and volume

(2) Accurately calculating the market shares, consumption, and other vital factors of different segments of the global Peptide CDMO market

(3) Exploring key dynamics of the global Peptide CDMO market

(4) Highlighting important trends of the global Peptide CDMO market in terms of production, revenue, and sales

(5) Deeply profiling top players of the global Peptide CDMO market and showing how they compete in the industry

(6) Studying manufacturing processes and costs, product pricing, and various trends related to them

(7) Showing the performance of different regions and countries in the global Peptide CDMO market

(8) Forecasting the market size and share of all segments, regions, and the global market.

Important Questions Answered included in the Report:-

(A) What is the market size and growth rate of the global and regional market by various segments?

(B) What is the market size and growth rate of the market for selective Countries?

(C) Which region or sub-segment is expected to drive the market in the forecast period?

(D) What factors are estimated to drive and restrain the market growth?

(E) What are the key technology and market trends shaping the market?

(F) what are the key opportunity in the market?

(G) Who are the leading manufacturers operating in the global Peptide CDMO market?

(H) Which key player accounted for the highest market share?

(I) What are the growth opportunities for the new entrants in the global Peptide CDMO market?

Table of Contents - Major Key Points:

1 Market Overview
1.1 Peptide CDMO Product Introduction
1.2 Global Peptide CDMO Market Size Forecast (2020-2031)
1.3 Peptide CDMO Market Trends & Drivers
1.3.1 Peptide CDMO Industry Trends
1.3.2 Peptide CDMO Market Drivers & Opportunity
1.3.3 Peptide CDMO Market Challenges
1.3.4 Peptide CDMO Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Peptide CDMO Players Revenue Ranking (2024)
2.2 Global Peptide CDMO Revenue by Company (2020-2025)
2.3 Key Companies Peptide CDMO Manufacturing Base Distribution and Headquarters
2.4 Key Companies Peptide CDMO Product Offered
2.5 Key Companies Time to Begin Mass Production of Peptide CDMO
2.6 Peptide CDMO Market Competitive Analysis
2.6.1 Peptide CDMO Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Peptide CDMO Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide CDMO as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 APIs and Intermediates
3.1.2 FDF
3.2 Global Peptide CDMO Sales Value by Type
3.2.1 Global Peptide CDMO Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Peptide CDMO Sales Value, by Type (2020-2031)
3.2.3 Global Peptide CDMO Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Commercial
4.1.2 Academic Research
4.1.3 Other
4.2 Global Peptide CDMO Sales Value by Application
4.2.1 Global Peptide CDMO Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Peptide CDMO Sales Value, by Application (2020-2031)
4.2.3 Global Peptide CDMO Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Peptide CDMO Sales Value by Region
5.1.1 Global Peptide CDMO Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Peptide CDMO Sales Value by Region (2020-2025)
5.1.3 Global Peptide CDMO Sales Value by Region (2026-2031)
5.1.4 Global Peptide CDMO Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Peptide CDMO Sales Value, 2020-2031
5.2.2 North America Peptide CDMO Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Peptide CDMO Sales Value, 2020-2031
5.3.2 Europe Peptide CDMO Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Peptide CDMO Sales Value, 2020-2031
5.4.2 Asia Pacific Peptide CDMO Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Peptide CDMO Sales Value, 2020-2031
5.5.2 South America Peptide CDMO Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Peptide CDMO Sales Value, 2020-2031
5.6.2 Middle East & Africa Peptide CDMO Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Peptide CDMO Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Peptide CDMO Sales Value, 2020-2031
6.3 United States
6.3.1 United States Peptide CDMO Sales Value, 2020-2031
6.3.2 United States Peptide CDMO Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Peptide CDMO Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Peptide CDMO Sales Value, 2020-2031
6.4.2 Europe Peptide CDMO Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Peptide CDMO Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Peptide CDMO Sales Value, 2020-2031
6.5.2 China Peptide CDMO Sales Value by Type (%), 2024 VS 2031
6.5.3 China Peptide CDMO Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Peptide CDMO Sales Value, 2020-2031
6.6.2 Japan Peptide CDMO Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Peptide CDMO Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Peptide CDMO Sales Value, 2020-2031
6.7.2 South Korea Peptide CDMO Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Peptide CDMO Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Peptide CDMO Sales Value, 2020-2031
6.8.2 Southeast Asia Peptide CDMO Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Peptide CDMO Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Peptide CDMO Sales Value, 2020-2031
6.9.2 India Peptide CDMO Sales Value by Type (%), 2024 VS 2031
6.9.3 India Peptide CDMO Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Bachem
7.1.1 Bachem Profile
7.1.2 Bachem Main Business
7.1.3 Bachem Peptide CDMO Products, Services and Solutions
7.1.4 Bachem Peptide CDMO Revenue (US$ Million) & (2020-2025)
7.1.5 Bachem Recent Developments
7.2 PolyPeptide
7.2.1 PolyPeptide Profile
7.2.2 PolyPeptide Main Business
7.2.3 PolyPeptide Peptide CDMO Products, Services and Solutions
7.2.4 PolyPeptide Peptide CDMO Revenue (US$ Million) & (2020-2025)
7.2.5 PolyPeptide Recent Developments
7.3 CordenPharma
7.3.1 CordenPharma Profile
7.3.2 CordenPharma Main Business
7.3.3 CordenPharma Peptide CDMO Products, Services and Solutions
7.3.4 CordenPharma Peptide CDMO Revenue (US$ Million) & (2020-2025)
7.3.5 CordenPharma Recent Developments
7.4 AmbioPharm
7.4.1 AmbioPharm Profile
7.4.2 AmbioPharm Main Business
7.4.3 AmbioPharm Peptide CDMO Products, Services and Solutions
7.4.4 AmbioPharm Peptide CDMO Revenue (US$ Million) & (2020-2025)
7.4.5 AmbioPharm Recent Developments
7.5 USV Peptides
7.5.1 USV Peptides Profile
7.5.2 USV Peptides Main Business
7.5.3 USV Peptides Peptide CDMO Products, Services and Solutions
7.5.4 USV Peptides Peptide CDMO Revenue (US$ Million) & (2020-2025)
7.5.5 USV Peptides Recent Developments
7.6 Thermofischer
7.6.1 Thermofischer Profile
7.6.2 Thermofischer Main Business
7.6.3 Thermofischer Peptide CDMO Products, Services and Solutions
7.6.4 Thermofischer Peptide CDMO Revenue (US$ Million) & (2020-2025)
7.6.5 Thermofischer Recent Developments
7.7 Bio Basic
7.7.1 Bio Basic Profile
7.7.2 Bio Basic Main Business
7.7.3 Bio Basic Peptide CDMO Products, Services and Solutions
7.7.4 Bio Basic Peptide CDMO Revenue (US$ Million) & (2020-2025)
7.7.5 Bio Basic Recent Developments
7.8 JPT
7.8.1 JPT Profile
7.8.2 JPT Main Business
7.8.3 JPT Peptide CDMO Products, Services and Solutions
7.8.4 JPT Peptide CDMO Revenue (US$ Million) & (2020-2025)
7.8.5 JPT Recent Developments
7.9 Genscript
7.9.1 Genscript Profile
7.9.2 Genscript Main Business
7.9.3 Genscript Peptide CDMO Products, Services and Solutions
7.9.4 Genscript Peptide CDMO Revenue (US$ Million) & (2020-2025)
7.9.5 Genscript Recent Developments
7.10 Xinbang Pharma
7.10.1 Xinbang Pharma Profile
7.10.2 Xinbang Pharma Main Business
7.10.3 Xinbang Pharma Peptide CDMO Products, Services and Solutions
7.10.4 Xinbang Pharma Peptide CDMO Revenue (US$ Million) & (2020-2025)
7.10.5 Xinbang Pharma Recent Developments
7.11 ScinoPharm
7.11.1 ScinoPharm Profile
7.11.2 ScinoPharm Main Business
7.11.3 ScinoPharm Peptide CDMO Products, Services and Solutions
7.11.4 ScinoPharm Peptide CDMO Revenue (US$ Million) & (2020-2025)
7.11.5 ScinoPharm Recent Developments
7.12 SN Biopharm
7.12.1 SN Biopharm Profile
7.12.2 SN Biopharm Main Business
7.12.3 SN Biopharm Peptide CDMO Products, Services and Solutions
7.12.4 SN Biopharm Peptide CDMO Revenue (US$ Million) & (2020-2025)
7.12.5 SN Biopharm Recent Developments
7.13 CBL
7.13.1 CBL Profile
7.13.2 CBL Main Business
7.13.3 CBL Peptide CDMO Products, Services and Solutions
7.13.4 CBL Peptide CDMO Revenue (US$ Million) & (2020-2025)
7.13.5 CBL Recent Developments
7.14 Piramal Pharma
7.14.1 Piramal Pharma Profile
7.14.2 Piramal Pharma Main Business
7.14.3 Piramal Pharma Peptide CDMO Products, Services and Solutions
7.14.4 Piramal Pharma Peptide CDMO Revenue (US$ Million) & (2020-2025)
7.14.5 Piramal Pharma Recent Developments
7.15 CPC Scientific
7.15.1 CPC Scientific Profile
7.15.2 CPC Scientific Main Business
7.15.3 CPC Scientific Peptide CDMO Products, Services and Solutions
7.15.4 CPC Scientific Peptide CDMO Revenue (US$ Million) & (2020-2025)
7.15.5 CPC Scientific Recent Developments
8 Industry Chain Analysis
8.1 Peptide CDMO Industrial Chain
8.2 Peptide CDMO Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Peptide CDMO Sales Model
8.5.2 Sales Channel
8.5.3 Peptide CDMO Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

About Us:

QYResearch established as a research firm in 2007 and have since grown into a trusted brand amongst many industries. Over the years, we have consistently worked toward delivering high-quality customized solutions for wide range of clients ranging from ICT to healthcare industries. With over 50,000 satisfied clients, spread over 80 countries, we have sincerely strived to deliver the best analytics through exhaustive research methodologies.

Contact Us:

Arshad Shaha | Marketing Executive

QY Research, INC.
315 Work Avenue, Raheja Woods,
Survey No. 222/1, Plot No. 25, 6th Floor,
Kayani Nagar, Yervada, Pune 411006, Maharashtra
Tel: +91-8669986909
Emails - arshad@qyrindia.com
Web - https://www.qyresearch.in

This release was published on openPR.